Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482800 | 0.94 | CNR2 (0.45) | CNR2AKT1CTSSCTSKKMT2A | |
| SCHEMBL13449911 | 0.92 | CNR2 (0.44) | CNR2AKT1CTSSCTSKKMT2A | |
| SCHEMBL15103109 | 0.87 | CNR2 (0.41) | CNR2AKT1CTSSCTSKKMT2A | |
| SCHEMBL15217048 | 0.84 | AKT1 (0.39) | CNR2AKT1CTSSKMT2AALDH1A1 | |
| SCHEMBL15217046 | 0.84 | CNR2 (0.38) | CNR2AKT1CTSSKMT2AALDH1A1 | |
| SCHEMBL25828122 | 0.83 | CNR2 (0.46) | CNR2CTSSCTSKKMT2AALDH1A1 | |
| SCHEMBL31021352 | 0.81 | CTSS (0.40) | CNR2AKT1CTSSCTSKKMT2A | |
| SCHEMBL31021337 | 0.80 | CTSS (0.40) | CNR2AKT1CTSSCTSKKMT2A | |
| SCHEMBL283816 | 0.79 | LMNA (0.38) | CNR2KMT2AGAAMEN1 | |
| SCHEMBL283815 | 0.79 | LMNA (0.38) | CNR2KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2411371-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2411370-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8288428-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-10-16 | — | — | US | disclosed |
| US-8236822-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2411370-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249086-A1 | Compounds As Cannabinoid Receptor Ligands | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111573-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885AKT1 1481/4885CTSS 2373/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | CNR2 2/4885AKT1 1481/4885CTSS 2373/4885 |
| US-20100249087-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885AKT1 1443/4885CTSS 2174/4885 |
| US-20100249086-A1 | Compounds As Cannabinoid Receptor Ligands | CNR1, CNR2, GPR18 | CNR2 2/4885AKT1 1814/4885CTSS 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.